Summary
Fifty-two patients with Fredrickson Type IIb or Type IV hyperlipidaemia, in whom diet had not achieved satisfactory lipid levels, completed a double blind randomised study of acipimox versus placebo. The patients were given acipimox, 250 mg three times daily or placebo for a three month period, and plasma lipids and glucose were monitored.
The patients receiving acipimox showed a fall in the mean concentration of plasma triglyceride compared to placebo (0.74 mmol/l) and this was most marked in patients whose initial plasma triglyceride levels were greater than 3 mmol/l (1.0 mmol/l, confidence limits 0.18, 1.82). Acipimox was well tolerated, and could be a useful addition to the drugs available for the treatment of patients with hypertriglyceridaemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kannel EB, Castelli WP, Gordon T, McNamara PM (1971) Serum cholesterol, Lipoproteins, and the risk of coronary heart disease. Ann Intern Med 74[1]: 1–12
Carlson LA, Bottiger LE (1972) Ischaemic heart disease in relation to fasting levels of plasma triglycerides and cholesterol. Stockholm Prospective study. Lancet 1: 865–869
Fuccella L, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, Sirtoli C (1980) Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 28 [6]: 790–795
Stirling C, McAleer M, Reckless JPD, Campbell RR, Mundy D, Betteridge DJ, Foster K (1985) Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 68: 83–88
Regal (1984) Effects of a single oral dose of acipimox on glucose utilisation after intravenous glucose load in obese patients. Drugs Exptl Clin Res 10: 621–625
Ononogbu I, Lewis B (1976) Lipoprotein fractionation by a precipitation method. Clin Chim Acta 71: 397–402
Gidez LI, Miller GJ, Burstein M, Siagle S, Eder HA (1982) Separation and quantitation of subclasses of human high density lipoprotein by a simple precipitation procedure. J Lipid Res 23: 1203–1283
Burstein M, Scholnick H, Martin R (1970) Rapid method for the isolation of lipoproteins from human sera. Precipitation with polyanions. J Lipid Res 11: 583–589
Robertson G, Cramp DG (1970) An evaluation of cholesterol determinations in serum and serum lipoprotein fractions by a semi-automated fluorimetric method. J Clin Pathol 23: 243–245
Cramp DG, Robertson G (1968) The fluorimetric assay of triglycerides by a semi-automated method. Ann Biochem 25: 246–251
Consensus conference (1984) Treatment of hyperlipidaemia. Am Med Assoc 251 [9]: 1196–1200
Sirtori C (1981) Reduced triglyceridaemia and increase high density lipoprotein cholesterol after treatment with acipimox, a new inhibitor of lipolysis. Atherosclerosis 38: 267–271
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dauber TR (1977) High density lipoproteins as a protective factor against coronary heart disease. The Framingham study. Am J Med 62: 707–711
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ball, M.J., Vella, M., Rechlass, J.P.D. et al. Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial. Eur J Clin Pharmacol 31, 201–204 (1986). https://doi.org/10.1007/BF00606659
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606659